Literature DB >> 11709513

A randomised controlled trial of high versus low long chain triglyceride whole protein feed in active Crohn's disease.

K Leiper1, J Woolner, M M Mullan, T Parker, M van der Vliet, S Fear, J M Rhodes, J O Hunter.   

Abstract

BACKGROUND: Polymeric feeds have shown variable efficacy in active Crohn's disease (CD) with remission rates from 36% to 82%. Meta-analyses of elemental, peptide, and whole protein feeds have shown a strong negative correlation between remission rate in CD and the long chain triglyceride (LCT) content of the feed. We performed a randomised controlled double blind trial in patients with active CD comparing two single whole protein feeds with LCT supplying 5% or 30% of the total energy.
METHODS: Fifty four patients with active CD (Crohn's disease activity index (CDAI) >200, serum C reactive protein (CRP) 10 mg/l) were randomised to a high or low LCT feed for three weeks. The total amount of energy supplied by fat was identical in the two feeds. Remission was defined as a CDAI < or =150 and response as a fall in CDAI of > or =70 or a CRP <10 mg/l.
RESULTS: Overall remission rate by intention to treat was 26% for the low LCT feed and 33% for the high LCT feed (p=0.38). Response was achieved in 33% with the low LCT and in 52% with the high LCT feed (p=0.27). CRP <10 mg/l was achieved in 30% in the low LCT and 33% in the high LCT group (p=0.99). Thirty nine per cent (21/54) of patients withdrew before three weeks because of inability to tolerate the diet. Excluding patients unable to tolerate the diet, remission rates were 46% for low LCT and 45% for high LCT (p=0.99). DISCUSSION: This trial has shown no difference in the effect of low and high LCT whole protein feeds in active CD. The previously reported correlation between LCT content of diet and response in active CD is unlikely to be due to LCT itself and may be due to some other component of high LCT feeds.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11709513      PMCID: PMC1728544          DOI: 10.1136/gut.49.6.790

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  22 in total

1.  [Animal experiment studies of ultrastructural changes in the lamina propria of the ileum caused by dietary fats and comparison with cytopathology in Crohn disease].

Authors:  E Nagel; S Schattenfroh; S Bühner; M Bartels; E Guthy; R Pichlmayr
Journal:  Z Gastroenterol       Date:  1993-12       Impact factor: 2.000

Review 2.  Enteral nutrition as primary therapy in Crohn's disease.

Authors:  F Fernández-Bañares; E Cabré; F González-Huix; M A Gassull
Journal:  Gut       Date:  1994-01       Impact factor: 23.059

3.  Basal metabolic rate: comments on the new equations.

Authors:  W P James
Journal:  Hum Nutr Clin Nutr       Date:  1985

4.  Elemental diet as primary treatment of acute Crohn's disease: a controlled trial.

Authors:  C O'Moráin; A W Segal; A J Levi
Journal:  Br Med J (Clin Res Ed)       Date:  1984-06-23

5.  Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study.

Authors:  W R Best; J M Becktel; J W Singleton; F Kern
Journal:  Gastroenterology       Date:  1976-03       Impact factor: 22.682

6.  Long-chain triglycerides reduce the efficacy of enteral feeds in patients with active Crohn's disease.

Authors:  S J Middleton; J T Rucker; G A Kirby; A M Riordan; J O Hunter
Journal:  Clin Nutr       Date:  1995-08       Impact factor: 7.324

7.  Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group.

Authors:  E J Irvine; B Feagan; J Rochon; A Archambault; R N Fedorak; A Groll; D Kinnear; F Saibil; J W McDonald
Journal:  Gastroenterology       Date:  1994-02       Impact factor: 22.682

8.  Omega-3 fatty acids and low carbohydrate diet for maintenance of remission in Crohn's disease. A randomized controlled multicenter trial. Study Group Members (German Crohn's Disease Study Group).

Authors:  H Lorenz-Meyer; P Bauer; C Nicolay; B Schulz; J Purrmann; W E Fleig; C Scheurlen; I Koop; V Pudel; L Carr
Journal:  Scand J Gastroenterol       Date:  1996-08       Impact factor: 2.423

9.  Enteral feeding as sole treatment for Crohn's disease: controlled trial of whole protein v amino acid based feed and a case study of dietary challenge.

Authors:  A H Raouf; V Hildrey; J Daniel; R J Walker; N Krasner; E Elias; J M Rhodes
Journal:  Gut       Date:  1991-06       Impact factor: 23.059

10.  Polymeric enteral diets as primary treatment of active Crohn's disease: a prospective steroid controlled trial.

Authors:  F González-Huix; R de León; F Fernández-Bañares; M Esteve; E Cabré; D Acero; A Abad-Lacruz; M Figa; M Guilera; R Planas
Journal:  Gut       Date:  1993-06       Impact factor: 23.059

View more
  13 in total

Review 1.  Nutritional therapy for active Crohn's disease.

Authors:  Paul-A Smith
Journal:  World J Gastroenterol       Date:  2008-07-21       Impact factor: 5.742

Review 2.  New insights into the role of fatty acids in the pathogenesis and resolution of inflammatory bowel disease.

Authors:  Darla R Shores; David G Binion; Bruce A Freeman; Paul R S Baker
Journal:  Inflamm Bowel Dis       Date:  2010-12-03       Impact factor: 5.325

3.  An elemental diet controls inflammation in indomethacin-induced small bowel disease in rats: the role of low dietary fat and the elimination of dietary proteins.

Authors:  Hideki Suzuki; Nozomi Hanyou; Ichiro Sonaka; Hisanori Minami
Journal:  Dig Dis Sci       Date:  2005-10       Impact factor: 3.199

4.  A survey of people with inflammatory bowel disease to investigate their views of food and nutritional issues.

Authors:  L Kinsey; S Burden
Journal:  Eur J Clin Nutr       Date:  2016-04-27       Impact factor: 4.016

5.  Treatment of active Crohn's disease in children using partial enteral nutrition with liquid formula: a randomised controlled trial.

Authors:  T Johnson; S Macdonald; S M Hill; A Thomas; M S Murphy
Journal:  Gut       Date:  2005-09-14       Impact factor: 23.059

6.  Translocation of Crohn's disease Escherichia coli across M-cells: contrasting effects of soluble plant fibres and emulsifiers.

Authors:  Carol L Roberts; Asa V Keita; Sylvia H Duncan; Niamh O'Kennedy; Johan D Söderholm; Jonathan M Rhodes; Barry J Campbell
Journal:  Gut       Date:  2010-09-02       Impact factor: 23.059

Review 7.  Diets for inflammatory bowel disease: What do we know so far?

Authors:  Clara Serrano-Moreno; Noemi Brox-Torrecilla; Loredana Arhip; Inmaculada Romero; Ángela Morales; M Luisa Carrascal; Cristina Cuerda; Marta Motilla; Miguel Camblor; Cristina Velasco; Irene Bretón
Journal:  Eur J Clin Nutr       Date:  2022-01-22       Impact factor: 4.884

Review 8.  The role of enteral nutrition in patients with inflammatory bowel disease: current aspects.

Authors:  John K Triantafillidis; Costas Vagianos; Apostolos E Papalois
Journal:  Biomed Res Int       Date:  2015-02-22       Impact factor: 3.411

9.  Interventions for fatigue in inflammatory bowel disease.

Authors:  Dawn Farrell; Micol Artom; Wladyslawa Czuber-Dochan; Lars P Jelsness-Jørgensen; Christine Norton; Eileen Savage
Journal:  Cochrane Database Syst Rev       Date:  2020-04-16

Review 10.  Enteral nutritional therapy for induction of remission in Crohn's disease.

Authors:  Neeraj Narula; Amit Dhillon; Dongni Zhang; Mary E Sherlock; Melody Tondeur; Mary Zachos
Journal:  Cochrane Database Syst Rev       Date:  2018-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.